IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

With Three More In Q4, 2020 Total Reaches 61

The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.

Businessman presses button ipo Initial Public Offering diagram online network. - Image
58 IPOs through Q3 in the US grossed $12.5bn with a 49.4% average return • Source: Shutterstock

The market for biopharmaceutical initial public offerings in the US has grown more impressive in each quarter of 2020 in almost every way. There were nine IPOs in the first quarter, 20 in the second and 29 in the third quarter for a total of 58 first-time offerings by drug developers – eight more than the 50 IPOs for all of 2019. 

Also, the 29 companies that went public in the first two quarters of this year grossed $7.2bn and with 29...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By 

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By 

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.